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Materials and Methods: In vitro, we examined the effect of 
AT-101 (kindly provided by Ascenta Therapeutics Inc.) 
radiation and the combination on apoptosis induction and 
clonogenic survival in two HNSCC cell lines that expressed 
the target proteins: UM-SCC-11B (derived from a primary 
tumor of the larynx) and VU-SCC-OE (derived from a primary 
tumor of the oral cavity). Apoptosis was determined by bis-
benzimide staining to detect morphological nuclear changes 
and/or by propidium iodide staining and flow-cytometry 
analysis to quantify sub-diploid apoptotic nuclei. The type of 
interaction between AT-101 and radiation was evaluated by 
determining the Combination Index (CI) and isobolographic 
analysis. In addition, we assessed clonogenic survival upon 
combined treatment in the VU-SCC-OE cell line. In the 
clinical study, N07CRH, patients with locally advanced 
HNSCC, were enrolled in a two-arm trial design with standard 
radiotherapy/cisplatin treatment combined with concurrent 
dose-escalating oral AT-101 according to two different 
schedules, a 2-weeks daily schedule every 3 weeks, and a 
pulse-dose schedule on 3 consecutive days, every 3 weeks. 
Blood samples were collected and serum concentrations of 
AT-101 were determined by HPLC methods. 
Results: In vitro results showed that AT-101 (10-15 μM) 
enhances radiation(5Gy)-induced apoptosis with CI's ranging 
from 1.1 (additive) to 0.74 (synergistic). Clonogenic survival 
assays showed a radiosensitizing effect with a DEF37 of 1.3 at 
concentrations of AT-101 that were markedly lower than used 
for apoptosis studies. Patients tolerated AT-101 well up to 
doses of 20 mg. Pharmacokinetic analyses of blood samples 
taken from the patients at time intervals from 30 minutes up 
to 24 hours after oral intake showed a dose-dependent 
increase in serum concentration with peak concentrations up 
to 300 - 700 ng/ml (0.5 – 1.2 μM) between 2 and 2.5 hours 
after intake. 
Conclusions: AT-101 is a competent enhancer of radiation-
induced apoptosis in HNSCC in vitro. In addition, in vitro 
radiosensitization was observed at clinically achievable serum 
levels. These finding support further evaluation of the 
combination of AT-01 with radiation in Bcl-2-overexpressing 
tumors.  
   
PO-1061   
Radiosensitisation properties of PI3K/AKT inhibitor GDC-
0941 in prostate cancer cells 
R. Floyd1, N. McDermott1, A. Meunier1, L. Marignol1 
1Trinity Centre for Health Sciences, Radiation Therapy Dept., 
Dublin 8, Ireland Republic of  
 
Purpose/Objective: Radiation therapy is a primary treatment 
modality for prostate cancer. Over activation of the 
phosphoinositide 3-kinase (PI3K) pathway causes 
radioresistance increasing cell survival following radiation, 
resulting in treatment failure and disease recurrence. 
Downstream effects of PI3K increase HIF1-α concentrations 
resulting in high levels of hypoxia in PI3K activated prostate 
cancer cells. This study investigated the effect of PI3K 
inhibitor, GDC-0941, on the radiosensitisation of cell lines 
DU145 and 22Rv1 under hypoxic and normoxic conditions. 
Materials and Methods: GDC-0941 was combined with 
radiation treatment to assess the radiosensitisation effect in 
DU145 and 22Rv1 cell lines. GDC-0941 was also tested under 
hypoxic conditions to assess if radiosensitivity was 
maintained. Clonogenic assays were used to assess cell 
survival under the varied treatment conditions. 
Results: GDC-0941 was shown to enhance radiosensitivity in 
both 22Rv1 (2Gy: SER=1.7, p=0.038) and DU145 (2Gy: SER=2, 
p=0.0025). The radiosensitisation conferred was also 
significant under hypoxic conditions in 22Rv1 (2Gy: SER=2, 
p=0.0155) although non-significant in DU145 (2Gy: SER=1.1, 
p=0.1835). GDC-0941 showed comparable radiosensitisation 
under both normoxic and hypoxic conditions in both cell 
lines. 
Conclusions: GDC-0941 radiosensitised prostate cancer cells 
under hypoxic and normoxic conditions. 
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Purpose/Objective: The anti-neoplastic compound Paclitaxel 
(Taxol®) is adopted for multiple strategies of cancer 
treatment encompassing classic chemotherapy on the one 
side as well as adjuvant treatment settings that combine 
chemotherapy with other treatment modalities like radiation 
therapy on the other. The molecular mechanism(s) by which 
Paclitaxel exerts radiosensitization of tumor cells is not 
understood in full detail. Moreover, the doses of Paclitaxel 
that are currently applied in the clinic often coincide with 
side effects of major severity. Finally, no stratification 
markers that allow for predicting the responsiveness of 
tumors towards treatment schedules involving Paclitaxel and 
radiotherapy are available thus far. 
Materials and Methods: Multiple concentrations of Paclitaxel 
were screened for respective effects on the viability and the 
proliferation of tumor cells. After identifying low nanomolar 
doses of Paclitaxel to impact tumor cell proliferation and – 
viability in a hitherto highly neglected manner, a cohort of 
tumor cell lines was screened for individual differences in 
susceptibility towards equivalent doses of Paclitaxel, either 
administered alone or in combination with irradiation. Based 
on this screen, a search for new stratification markers was 
performed.  
Results: We show that Paclitaxel at lower nanomolar 
concentrations effectively sensitizes tumor cells towards 
ionizing radiation by facilitating high-grade aneuploidization. 
At such concentrations, Paclitaxel renders the ordinary, 
bipartite mode of cell division into a highly non-equational, 
mainly tripartite one thereby facilitating huge levels of 
aneuploidization and this is frequently followed by a distinct 
kind of apoptotic cell death. We show that this effect can be 
correlated with Paclitaxel-dependent radiosensitization of 
tumor cells since cell lines that are resistant to it are 
sensitized to lesser extends. We also provide evidence that 
both, Paclitaxel-dependent aneuploidization and – 
radiosensitization of tumor cells correlate with the 
expression levels of AURKA and TPX2, two proteins involved 
in mitotic spindle assembly, since a knockdown of TPX2 not 
only rescues the bipartite mode of cell division in the 
presence of Paclitaxel but also diminishes the 
radiosensitization effect that is achieved by Paclitaxel.  
